Feedback / Questions
lusvertikimab (OSE-127) - OSE Immunotherapeutics
http://clinicaltrials.gov/ct2/show/NCT04882007
Jun 23, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next